Parkinsonism Associated with Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy
Overview
Overview
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Caroff S, Jain R, Morley J
. Revisiting amantadine as a treatment for drug-induced movement disorders. Ann Clin Psychiatry. 2020; 32(3):198-208.
View
2.
Mishra A, Gupta A, Dagar G, Das D, Chakraborty A, Haque S
. CAR-T-Cell Therapy in Multiple Myeloma: B-Cell Maturation Antigen (BCMA) and Beyond. Vaccines (Basel). 2023; 11(11).
PMC: 10674477.
DOI: 10.3390/vaccines11111721.
View
3.
Cohen A, Parekh S, Santomasso B, Gallego Perez-Larraya J, van de Donk N, Arnulf B
. Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies. Blood Cancer J. 2022; 12(2):32.
PMC: 8873238.
DOI: 10.1038/s41408-022-00629-1.
View
4.
Hayden P, Roddie C, Bader P, Basak G, Bonig H, Bonini C
. Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European.... Ann Oncol. 2021; 33(3):259-275.
DOI: 10.1016/j.annonc.2021.12.003.
View
5.
Van Oekelen O, Aleman A, Upadhyaya B, Schnakenberg S, Madduri D, Gavane S
. Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy. Nat Med. 2021; 27(12):2099-2103.
PMC: 8678323.
DOI: 10.1038/s41591-021-01564-7.
View